Business · 03/04/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for INJECTAFER Patent Extension Application
Summary
The FDA has determined the regulatory review period for INJECTAFER, a human drug product, following a patent extension application to the USPTO. The Agency is publishing this notice as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →